Inventiva (NASDAQ:IVA) Shares Gap Down - Should You Sell?

Key Points

• Inventiva's shares gapped down from a previous close of $4.96 to open at $4.75 before rebounding to $5.20.
• Despite the recent price drop, multiple analysts have given the stock a "buy" rating, with price targets ranging from $13.00 to $26.00.
• Institutional investors now hold 19.06% of Inventiva's stock, indicating growing interest among larger investment firms.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $4.96, but opened at $4.75. Inventiva shares last traded at $5.20, with a volume of 196,279 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms recently commented on IVA. Canaccord Genuity Group restated a "buy" rating and issued a $20.00 price target on shares of Inventiva in a research note on Tuesday, September 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Inventiva in a research note on Wednesday, October 8th. HC Wainwright upped their price target on shares of Inventiva from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, October 9th. Piper Sandler assumed coverage on shares of Inventiva in a research report on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 target price for the company. Finally, Guggenheim upped their price target on shares of Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Inventiva has an average rating of "Moderate Buy" and an average price target of $16.14.

Inventiva Stock Up 10.3%

The business's 50 day moving average price is $5.19 and its two-hundred day moving average price is $3.97.

Institutional Investors Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.